ADAP - Earnings call transcript Q2 2018 | Adaptimmune Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q2 2018 Adaptimmune Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I will now turn the call over to Juli Miller.

You may begin.

Juli Miller

Good morning, and welcome to Adaptimmune's conference call to discuss our second quarter 2018 financial results and other business updates. release please morning of review statements press ask I our a there. to you the issued earlier and this would forward-looking We full text

and and making brief a to with factors, in during we the a outlined of could anticipate I'll those latest for Officer the As to prepared this the this call materially reminder, Noble, Q&A. over for portion number call available is that, our actual including due me our our is Chief James. team with turn SEC. Executive call results differ projections With management of filings James? James

James Noble

now program are are have Juli. by July, confident place. our MAGE-AX Good assets. response having data hit track XXXX you, and and year remain out wholly-owned to for we across with assets. this those we us later milestones in a be runway to thank of the you We milestones. of at conviction later for for consistently brief and be all this joining year, we resources us. is transformational trials strong the and will GSK wholly-owned this and We clinical, we two year; Thank patient to of reinforced are that year, NY-ESO regulatory data on our the manufacturing set momentum positive with AFP our completed everyone, the call We'll transition beginning this messages be dedicating and will for morning, both deliver Today's also main and secondly, a First, MAGE-AXX programs the sharing safety initial in that:

review billion bladder, cells in MAGE-AXX tumor in transduced to dose in and announced escalation recommended January committee First, study cancers. that head the triple the and neck melanoma safety we X

dose our escalation cells in announced billion quarterly to with during call. last non-small MAGE-AXX cell cancer lung X study Secondly, the we

the cells MAGE-AX that to the these added committee we month will cells. of basket in dose as safety to in to synovial last review and dose that Thirdly, receive we MRCLS studies up study, sarcoma both a we dose billion recommended in X ASCO billion we escalation patients announced the cohort Fourthly, announced X third have and and escalated June MAGE-AXX at indications. additional

all second dosed, in escalation as patients safety Finally, study meet the MAGE-AX. have shortly committee the to been MAGE-AX three for to the for cohort cohort will dose review X review basket

In Munich, place recently delivered data as and and present addition, ESMO later we on and deliver Germany. please keeps poster MAGE-AX in projected us to through our year data had accepted XXXX projected. that track to far, in we October Thus this we MAGE-AX take this SPEAR T-cells response milestones will are Congress to by our have share a MAGE-AXX this against

of eligible strong studies. a We identified runway have for patients our

pass once cohort, which addition, phase, more be third will clinical dose allow momentum. we even a In able to stagger we'll to predetermined the patients gather us without

development we and lung endeavor. cancer, MRCLS, take with transition As across including SPEAR of to sarcoma, non-small reflect successful were a myeloma treated this on like and the indications, NY-ESO announced, back to moment we'd prior and including synovial and NY-ESO XX completed, the GSK was we cell recently melanoma, announced have cancer completion synovial sarcoma, to very several MRCLS program in patients favorable enrolled cell transition, multiple the T-cells ovarian to this we trials year, transition. in solid MRCLS. tumor, completed second and KEYTRUDA in We indications. data cancer In the the enrollment March with benefit study responses a seen risk combination to non-small the of prior these of lung

to many multiple sarcoma, lessons our MRCLS. our has in myeloma applying responses with The program seen ongoing have and As multiple studies a us wholly-owned in are assets, NY-ESO we including. responses complete both confirmed taught synovial and that our we reminder,

hypothesis First, that billion The correlates Cohort than synovial based from expansion of of in required is with SPEAR on there expansion; suboptimal sarcoma profile see the the T-cells responses think cells a the showed that dose data fewer we who of XXX X X received to secondly, that program, threshold cohorts is expansion patients program where and thirdly, patients days to responses. of of X and X dose of fludarabine program, days MAGE-AXX received dose the similar further against receiving MAGE-AX the strengthens matters; doses NY-ESO from this data Cohort in on synovial based in sarcoma million which looks lower patients the cell X respectively. X our that

received of receivable. important of the $XXX beyond XXXX, optimal are have million we extra that million day from as of to which third quarter fludarabine our incorporated in ongoing recent a with of financial result terms, the since $XX million concern, into receive fludarabine as total Therefore, response. far an and we of as day for NY-ESO, the studies. this brings the payments we've that determined the expansion $XXX have and GSK In is third We will transition cohorts extra

abstracts of now in successful that New CRI, receive the place of and take to Washington, will City upcoming Future November We subsequent based FITC, D.C. we have can but in GSK, Immunotherapy submitted the at in the and end International sales York the of which to milestones responsibility been Conference, will also also presentations NY-ESO September development of say program. development NY-ESO royalties and on data are

response target transitioned with a this Medical With effectively priorities. the Rafael's our of and prosecute allow AFP. together all the key can under our clinical for signal Development, leadership, single the MAGE-AXX, assumed trials. of in total we are pivot Under any our data clinical to completion or million and brings of result now a Xst R&D and and leadership, our effective the Rafael deliver have to and of to better than we positioned a Officer, announced MAGE-AX of which excludes identification to we new as whether this we the research to which, liquidity, regulatory of specific. indication of GSK This are regulatory and With clinical more morning coupled our has planning actively of delivery President manufacturing course, deliver see, transition, from resources integration the the payment dedicate funded and pipeline enabling target focus, will teams, and With NY-ESO $XXX to this To on from Amado, wholly-owned August. we $XX rapidly teams R&D of Research clinical from GSK, selection from are XXXX. of integration alignment role filings, more we all million as NY-ESO parts early through and registration Chief transition, that

will for first be solid with open market that T-cell Operator? we are our I'd achieve call up SPEAR tumors. We that, to goal the questions. to confident With like to in therapies

Operator

[Operator from Karnauskas Citi. Instructions] Robyn comes question Our from first

Robyn Karnauskas

I'm Hi, how guys. in year, my call data slowly, go -- you this all may to the you trying saying are seek you dose last higher than how you make terms cohort you you be to and trying patients. think very the in taking in do? cells through XX Thanks start congrats for up able going I last the question that, of you're for to when said remember to -- have just million to was on I just where progress. sometimes I not many that patients

patients many to other trying how I cohorts get? from can just So understand

James Noble

cells. just take answer to in manufacturing, the billions detail. Rafael the But let I'll of

and billion, which been X cells, often today cohort, than is X where billion the that That's more X patients. of area actually somewhere So most the X just just we've I'll and We been manufacturing. we all X second we've regularly achieve told achieve we common between for of is cells, doing, billion production billion recruited you MAGE-AX say achieved. normally

to X.X to XXX the up are So million essentially only billion, X there escalations to can is with is and next -- we dose, one, dose escalate. dose don't X dose We X although the billion, technical billion. billion the range which keep the escalate intend

terms In I'll the that let of Rafael point. take stagger,

Rafael Amado

Robyn. Yes,

So is conditioning. and moment the additional for observation the days stagger at of days potentially X X the

be between for it turns to So out patients. days XX dosing

there'll And products cohort patients are with so no able dose have X that is they making will finished, awaiting we be We And X. for will then to in that as patients stagger, cohort treatment. come. after been be continue we

that patients soon these be as will X to able treated cleared. So as has be we of cohort many anticipate

the And if Now to cell upper dose are be we'd dose, the is available of we I we're product the up cell that maximum many dose range going dose the Once further modification cleared, only any X, of cohort will goal us patient to allow in making dose infuse cell characterize X XX response to not a and obviously there terms dosing. one up more a X the fludarabine. in escalation. intensity billion, cohort the will changes we're is billion. to in of increasing X cells has The of as available, is, curve make that, will think the cells has other

Robyn Karnauskas

Got it.

think So for billion cells count cohort? it's X have until X what billion going after you so that billion number billion, can the only you patient, manufacturing do hit and so patients do if X and Or how yield percent billion for successfully versus you a just what of will fixed like of X that to keep far to do dose as to get at you just is? -- patients of for basically billion, cohort X in, enrolling can't make XX that, -- you're you okay them certain make it like X you happens people to above a curious billion, go much that in are just you I make tied when be can put was of this fixed. percent

Rafael Amado

is Yes, billion billion. of a X range X so to X.X cohort

for more a has X, within not completed. that that we If that will more than until are that receive range patients any infuse So evaluable cohort. patient dose gets cells escalation

would If the patients that we're of in manufacture billion to facility we able at say Navy not, manufacturing many -- Yard terms XX%-or-so. XX in half I In billion X how of probably are the patients. levels about about --

gives look those opportunity I So us that to an doses. at think higher

James Noble

bit year ago nobody it's common cells made out how more. moving that coming XX the target get billion in fact, it now is were manufacture, when Yes, to and billion but sometimes almost improvements people at the cells. I'd and a only we we a at nobody say and many before is X that billion manufacture, of XX a certain almost PCT of

Operator

question of next SunTrust from comes Peter Robinson Lawson Our Humphrey.

Peter Lawson

they to constant a of the data do you desire make GSK, release data, to get how And see that in data of going sense about of what get any thinking release? potentially you sense could and around kind a to frequently there flow a the of platform also NY-ESO? they're kind is validate sure going just think any we're you is James, do -- there do the

James Noble

as so said, and in Yes, be September year, one updates there'll one think this I November. I in two

I that to they think they're that if response focus -- trials. starting -- I larger we on going a see some that if think

think there they major think the update clearly but small in is fact is be I therapies, whenever going trials, pharma, tension. comment week there'll a last R&D so featured the -- to a had excitement I normally or which that at a and was I wouldn't between a natural their week GSK on when be tension think they cell it clear before

and media, anything responses that that I on extremely be known. because keep to our I happens. difficult from particular, tend to if And media doctors responses think also just think we social it's in be social see experience, lung to both will in if to own go clear, out cancer I patients of think

So actual or the including but things, be way presentations to of entirely it I will apart GSK, think those there up conferences. another two from one is

to have and you. with watch just we think I see So

Peter Lawson

control from you. that was thank really the the in worries title is, the stage about Rafael, any kind I for of going increased role efficiency there to R&D And Great, does clinical appreciated. stage? signal change then the or issues

James Noble

but type incredibly to data, look very actually, translational target doing it's you of generally -- which What receptors. it's appear mean, incredibly in the and on is patient essentially in the What time, T-cells goes inside make it It the is will, cells it want, T-cell we company I type the all important research can the is, not a at a an loop the patients? going okay, be that therapy have way quite the of cells back No, what's the what data, receptors, we real type and fact all feedback and -- an loop of cell back a feedback giving amazing we survives? the if let's is responses? loop integrated peptide, targets feedback to and can the find important make thing. into speaking, at find

of to example, the the first from selection that important. important put and all say, it one we're which second-generation clinic for very some is of incredibly very the programs, integrate I'd And stage. second-generation, right pick thing you one you excited the it's one So in about which into obviously

a way of really fact be from it through. and And -- the the to within be had it's function course Rafael all the from seamless all identification to regulatory target honest, way the So has GSK actually. that to same role actually of

So I emphasis. think an it's really, it's just

incredibly particular, I X in important in that, is think to keep as cell unit. feedback us therapy, that circle

Operator

Our Ren next James. from comes Benjamin question Raymond of

is line open. now Your

Reni Benjamin

efficacy in ASCO, was believe the Could that just somebody everyone Maybe MRCLS with an And at couple as where we who by Thanks there question as else just a you PR for give durability response us how questions. guys can to the there study? give guess has on a been had us off, chance guys. overall at data, mentioned I I kind and morning, congrats unconfirmed assessment. well. sense awaiting good but that taking you I the of is Hey, progress and the looked of know you results stands? on starting update was rate

James Noble

were months. can't of a have very were recently. patients a this over obviously, but months, earlier was who patients comment last we quite in lot the actually fairly the of really durability response actually many durable of X the year dosed dosed I because, we -- number patient X, mean or first a the had So on

So really have we don't durability.

X In and with we that's the unconfirmed. ended up we and was X where of of terms first And rates, ended response responses on X up. patients, those, confirmed

this which updated -- the that's being So in X -- is be updated that [Indiscernible] and what year will at later

Rafael Amado

patients to be XX response so entire at recently, [Indiscernible] on the first we [Indiscernible]. don't with able cohort patient where X X. we those, to treated report we and It's at yes, for the last outcomes have we hope so that's But the are

Reni Benjamin

this these And that love more and last okay. of call, just out a and I to kind bit believe per it, kind of is Got idea little your the one things -- on I'd of probe of other patients came the your and on of talk and how potentially has and a protocol, Can little been you can if patients to retreat these a bit about seen. what extending retreating up response is about date response durations you responses plan going thinking experience you of forward? retreatment

Rafael Amado

is on we a can number we So had and a time commented them in some GSK, hopefully, we've And response. in responded be retreatment experience so responses we say the had variable. will also before, the manufactured that patients past -- and And reinfusion as of manufacture and long physicians see them made we reinfusions the were didn't is that, in that actually fact GSK response transferring function in levels. because taken products dosing the the retreatment. also X saying be and I of early reinfusion Having so we reinfusions found of X low out the doses. X for not infused, that, But of hopefully a lower right cell upon patients reinfusion, transition of for for dosing patients have that progression, a probably last we the of the at ended really James Recently, some product we mean it patients that to benefit at the upon may actually said higher was -- to initially also we reinfused upon patients we're again, rate haven't we've and has seen been we expresses they able that requested But complete actually to a now, ago. will up that do. the have And place and durable. and patients But they that tumor last then least lot of and responded. antigen interesting than they

reinfusion. from to So benefit derived there is be

Reni Benjamin

as you're Rafael, regimen, once response? about, automatically follow-up you're the to about, I'm you've is guess preconditioning thinking kind And happens that again a reinfusing or do when just thinking that that the when just reinfuse you or something I of lost when

Rafael Amado

Yes, the and response of actually, what we are time so the at been first looking data cohort And we with type condition had everybody. receive they've detail because begin depended the enrolled in on condition to have they what around. kind of they

So some to up akin with for treated reinfused X. patients that X under ended Cohort conditioning were being Cohort

experience. at require entirety all just we'll infusion. redosing the to definitely look of to the so, And they prior But conditioning have

Reni Benjamin

it. Got

James Noble

looks certainly when and Cohort redosing some we first in than didn't a where hopeful see interesting time lot. more for we patients ago than It X redosed

the said, don't Rafael What and because any of X partial -- quite data we responses, X, we X As recent. that had we last redosed durability have X they're on X is complete.

Reni Benjamin

one in the Got talked then manufacturing. release the about believe time. final I it. shortening me mentioned manufacturing press expanding past with about for manufacturing. know we've the in And I you

And -- to anticipate the you will the will does really and the more current kind be that in? trials just of be come you are think clinical account so, started? expanding is of X of you it the is other, Or number for number trials before coming patients

James Noble

the than we're months, patient XX XX So our recruitment we more when to slots. next then because need at plans expanding, we for have look

the month form miss training and huge each is functioning people. to we've Navy to the very and time our essentially, get long XX capacity we with now basically of there to able what is is but is we What I lots because any didn't at and efficiently. some go think we of of are we what want the mainly people, So signal X slots us that called be if a and look at do leap MAGE-AX, up training slots patients a And there Yard. that functioning do want own number to to up Navy It is which terms in lots takes when to week build a it who during Hitachi got involves which out a XX year. -- we with extremely to well, well, to beyond knew quite push And capacity. need until expansion target, was we it Yard patients express next of of the patients, available out, lots of we in particularly PTT,

So part to of trial. all it's registration planning pivotal

You've obviously got available to have at more patients once.

you in Just remind cohort, earlier, what it's the well Rafael third the is between at finish said everything assuming there stagger so cohort that goes point, all safe. no when we third patients to

you cells, So need cohort, as essentially once situation if the third that actually than is. patient be current the ready stagger, you can't X rather say, to turns finish weeks the up, possible whatever you or manufacture dosed anyway, be because of well as to for

very is have moment. development a to call expansion at big combination going changes, it manufacturing in reducing doing it what's it's on, -- that to addition all of combination of the get involves what those is that's But completely going that, release the of trying the factors. and testing, efficiency side involves different of all That's on logistics, it's better parallel thing but it's a So that team, to we the process Along in shorter. a involves that. process that we better

Operator

Leerink Our comes Chang question Jonathan of next from Partners.

Jonathan Chang

taking thanks question. Hi, for my

and the to for the you whether you're talk thinking development, stages making safety and want question. decisions clinical benchmarks before target amount of you next indication efficacy specific? or about Can that see First data of about how go/no-go

James Noble

problem sort durable of a which had if X to So to at for about of have dose the or past. also product. least example, that's, you right reasonably there's think that then And in with and a talked rule at responses we've there's you XX freakish preconditioning, you the some have X patient a about not see explanation need relevant patients we've thumb, the with some

succeed commercially and patients XX -- the respond or if I response that only the for think is in X Cell and true. think X X holds therapy I only months. won't if

So that's been the rough benchmark.

the the or these multiple course, cancer that are indication specificity is comment fact antigen about Of trials.

cancers think I in trials. MAGE-AX the are So there X

anybody you than fantastic that consider with the into So tumors in in the saying X antigens might antigen you come tumors, their event rather presenting subject. thing those responses X different got doing this -- particular might

sarcoma of NY-ESO. into I if because think be pivotal to one think the worth we've we trial that, would all will seeing extremely begin a sarcoma, synovial exception is going where confident be with all it I with that I we straight responses, the data had think,

Jonathan Chang

that's Great, helpful.

data dose set of second how et question, patient levels expectations the and Second in and AX you help terms half, ahead MAGE-AXX cetera? can of the to numbers, follow-up, in just

James Noble

X patients each in there are dose level cohort. each So at

we X means dosed that cells billion have the the example, So to billion take in X billion as X call, if we all the that, X cells, mentioned I patients. MAGE-AX, for for

So that safety fairly can the committee that shortly. means meet review

patients still cells the got And after we to the X.X dosed to we go start assuming days XX committee. wait okay, then again go to We it's the committee up dosing earlier. says those billion have as hope stagger. the shortly, review the then we before review safety -- Rafael very mentioned X safety to last patient to billion up We X is

in MAGE-AX. be But more dose of at Once number it's the very stop only should people year, difficult the cohort review escalation, we'll approves just up go at next and dose exact committee a to safety there to be of billion that X particular give you patients dose. at the get dosing then and reasonable we to So by the won't the a numbers. cells X but end you

dosed data at and patients dose, can level we up. the billion X you'll then the the So at cell X many on next get get however

Jonathan Chang

whether assess cohorts, point MAGE-AXX to the one Okay, efficacy? can the ago time great. is there that about that With from me. weeks last talk advancing just regards then was to one dosing a announcement at third enough of you And to couple

James Noble

first you it patient meets not after you what days because way -- is And -- committee the get is safety days dosed. on XX and -- unconfirmed XX then that another you scan really that. response an So been confirmed last for you scan you difference the after And the the have have a is have patient essentially then. back has review -- the wouldn't then between do response the to last

a So the safety have the won't the It responses committee safety it have not data at only function dealing a just check, there shortly, of up the will MAGE-AX, review have they any and safety time. all. data. you of the wouldn't which dose. that's review at looking meets, It's obviously of that's have for; suitable And responses is when won't response is committee. with we simply just go committee it's who whether assess a -- it's The doctors same We'll to true is not do it's just safety the all data. at panel

Operator

Cowen of Frahm Company. Marc from comes question and next Our

line is open. Your

Marc Frahm

my taking for thanks Hey, question.

mentioned has a and that corporate you've Now that up effort. takes NY-ESO significant transitioned, of the in James past kind of amount

of is cell the into several clinic would either priority the put target in? step in one of And from not in then modeling existing up or we to should taken space down does the the some up that or in next capacity is even months going a spending perspective, be X and the just version by kind priority also new be the So getting the expect a the programs? to that immediately free generation a that

James Noble

we've that are it freed perfectly that, and because directions. programs would, as dovetails we is expanding work answer lots transitioned on staff, in hoped therefore GSK the has own as got our several the So in actively all up we it of

of is is We into course, a clinic next I study. pivotal it's procedure? as at planning. to we study, looking top amount to the irrespective what second for we example, go year. for at MAGE-AX looking And it target all do generation sites, is, and takes the that, pivotal are course, -- study a complex whether also next planning clinic of And which on the of the and of another into So, of a the to a program MAGE-AXX go European huge it which adding very mentioned, year, have or and pivotal are

just team the we're it's as for MAGE-AX the actually the other perfectly actually program series obviously. looking particularly also to has at a that old So evolved existing switched programs on over of priority the well, transition -- HLAs

So planning as a well. study, so expect at year a We're these. HLAs, to combination very program pilot we for is and full, we're another pivotal planning the generation maybe studies, -- second pipeline we're obviously other with looking next -- target for further studies another

it's and So that's incredibly what they're doing. complicated, And Europe. also

a things, it's our So we whole stack delighted of resources at have the that all but we're now. disposal

Marc Frahm

cleared. waiting the bolus capacity, out? expect it on is a we your then to operations levels kind is Or mitigations/clinical really spread of Okay, level those also that's of infused? And you just going once dose -- maybe patients to Should patients of your risk X like be a researching cleared, great. should get And manufactured from a the dose comments. just of earlier some kind patients just following to sounds for we up have backlog of cells some of there

James Noble

them, obviously then, will and are by to everything's out all the the we're we of stagger. cells, patient-by-patient and patients the gone whether many offer assuming well So We they they of ready because determine reason cells, through get obviously a go more the the cells, of else. to through X of X wants because, had haven't say, do the more going they're let's wants treatment do of medic because -- something X chemotherapy but doctor not to or more round stagger, the just

the amend patients. soon people, then we'll who have are, that's can be So obviously, we able as cell, the so what's of free, we is, them. a happened the list obviously well to essentially individual we but And have don't made time, as we've the protocols treat they at

of then free see go, stagger, for doctor would we and ready. where to want will have -- list of they whether go patients' whom a contacted made, once we're they're patients and been have We be cells the every single

Marc Frahm

mentioned you've liver -- expression last Okay. not and one. antigen antigen The with the maybe sufficient people mentioned -- year really functions the And you there then and ago, that people finding issue. was On finding you're with a enrollment about was of maybe safety one your data remaining able something criteria. timing ultimately in you meet past like and from was start changed seems then issue expression criteria, enrollment safety But AFP, you recent quarters that you're up in the the you is you've, efficacy haven't to that clearing kind presumably the do trial. it yet, or Have data of cohorts? moved once if can

Rafael Amado

hi. I'll address Yes, that.

this So been obviously because begun expression liver. were cautious in and normal thinking we actually initially, AFP some dose, about you're very there is study since the we've right. We've to particularly,

wanted of And so safety TCR. growing we if to we're more could you the we that Obviously, days, but will. we're ensure confident, the in that, early make sure

we've And patients that the very to come study, they one into levels. alpha-fetoprotein decided to of so the high have things is circulating do to allow

were high AFP. the now, expression circular IHC based past, During of the the only tumor in And criteria or by on immunohistochemistry. it's levels either

in lot done particularly of of where in excellent pool of a enrollment. increased for available past have the [Indiscernible]. the study we've second products patients And is like expand in Europe, the the that's So that the thing we -- sites participated have development in

that And the so pace of a more optimistic increase. bit will the we're study, recruitment

Operator

from comes question of JonesTrading. next Our Soumit Roy

open. line is Your

Soumit Roy

is Thanks for everyone. question. Rafael. taking for Maybe this the Hi, question

to Do tumor P-cells and I-O subtype and to from expand efficacy to to higher thinking are seeing NY-ESO dose form? versus MAGE-AX going level? cohort data T-cell you're to sense X, the the like a X, much is more on to are what patients confident treated, you these of get or the how trials trials billion see because where billion confident type much dose going And think like be in memory from to to you your want patients. possibly different you it's mutation going the also are X They're you synovial what's sarcoma -- this you it's burden. from compared from Just very X how going more efficacy type X, it's think higher MAGE-AXX, dictate see quality

Rafael Amado

question. great a that's Yes,

product eventual production. starting affect during dose the material variability have the can we So cell that obviously, that the an comes experience

to of taken activation head understand expansion we've been the a say variables melanoma suitable from range development types cancer, But at process multiple to And to the across manufacture pleased lead moment very dose. sarcoma myeloma wide a we're patients the key ovarian to and with team cell to so that successful are to that what lung. successfully time able some to obviously obviously, it's and neck, tumor and

great obviously see you the So that very all as patients tumor paying the of been so really are is the optimization it's diverse, is process types these very and off. different, to pretreatment know, and

potency, they In this patients, at the terms of targets. product, And administered. the look go in cell but seen to release they create ability to through that final large also also large killing. in samples we cells And we number actually exposed in a when so active. subset of haven't interferum patient, are done every we've of these the criteria before are And cells of

threshold X of doses encounter sufficient. that, of doses said for be and sarcoma, dose, cell we've X we've required of may above and the a of between in seen tumor also and in there's cells just NY-ESO matrix critical travel at MRCLS billion probably the terms Having responses. X seen I responses and antigen. to with In a synovial deposits to penetrate not low the billion cells tumor to in And these dose that's think,

may Cohort we're are in the going up middle obviously ruling of soon that only middle see to and for the that in we And that these the we're in can obviously, that treating in at be currently MAGE-AXX and So go not very of for moment positive the MAGE-AX. some X, X. cohort patients data we're out we in chances

in our are of at doing phase we efficacy So of the really of where products. programs development a X tests the these these are X we

Soumit Roy

up there at needs in high looking a a want to sense last Thank you. it I it? And What they percent enrolled with academically expresses for published have patients? screened how world papers, to question. cutoff getting do you're and the the as of really AX low was you get AXX? the match different real MAGE-AX you're of just and the are versus And enrolling MAGE-AXX trials, helpful. patients expresses be That one do see is or for Just of

James Noble

patient actually on So out the given numbers; haven't we screening data.

think types the NY-ESO by main to before that encouraging. looking actually the than MAGE-AXX public have encouraged that the adeno is that and we far data. present don't the many is people think lung were both MAGE-AX MAGE-AX, are for are I'd in across between how surprised, the domain people at that the tumor how and I the published TCJ, for we've halfway out cancer the and we're has pretty think told I MAGE-AX. I lower it's and the much say data. been very on we antigen -- the been very it which of prevalent data sticks database closely

you higher in both multiple the than be real sarcoma the myeloma which databases, database. in Sometimes and with of NY-ESO, would higher the that world. much expression example of get were An synovial

world. rarer, much I MAGE-AXX we reflects the expected. in think has lung real certainly pretty bit MAGE-AX been than a

Rafael Amado

is add a partnership is prevalence assay now Cancer is expression guess there of with Anderson to we're depending part very you're would because which MD I screen. Center, on we I select what use as we that important, routinely and have great assay using what testing alliance, the to patients, the with

And TCR, MAGE-AXX into for we're so, plan clinic. bring -- the we we've it it so future doing we're it MAGE-AX, done and and for the doing to

should XXXs what tumor real the are prevalence XXXs these of be exactly So know in and world. samples. the And banks we

a lot precision the of on get we So prevalent.

Operator

Our question comes of Securities. Fargo next from Birchenough Wells Jim

is line Your open.

Nicholas Abbott

morning. in Jim It's morning. Nick this good Hi, for

moving on in and are could that. trials use checkpoint And have integrating approved? for have where so how inhibitors checkpoint and plan think the Thank you. forward, as to question inhibitors inhibitors used where you protocols first you follow-on. would several tumors be The use a I But that about those you in relates believe I inhibitor checkpoint allow checkpoint the of tumors the --

Rafael Amado

Yes.

agent therapy. goal our this establish single optimize characterize initially a products. of these the activity to is against So Because to which we to baseline need do

patients are been inhibitor. have of we're You of PD-Xs. tumor that types we're studies, the the And in PD-X enrolling for indications to exposed are majority our including right, many Class

primary failures moved cancer, lung And assistance. acquire or some for in earlier therapies. and assistance, indications line been in PD-X the of like in have they're the these earlier So products

line. So many patients front getting PD-Xs are in

So a is a could is there And to regulatory preclinical potentially an of opportunity to space patients, to restore clinical developed. explore beginning be where in becoming is of combine entity, the PD-X that prevalent is very PD-X potentially and of PD-X there definition failure failure rationale them be there where the terms to to the which patients also products in sensitivity progressed. pool

have studies And alluded adopted this as technology with potential those of initiate transferred in So, the But agent started very ability in has goal T-cell single inhibitors. I to inhibitors, first to lung multiple and patients partners in with long is our where see And is helpful dose trials. X we try combine for trial. with with a characterize NY-ESO we that's combination and activity we're GSK TCR in therapy, complete for to and a planning are We is doing been our cancer. guess, myeloma. discussions that Jim few combination the the that's is. with mind, We cell PD-X on with non-small But to report transfer GSK which to particularly we before us to the escalation will prior the PD-X treated that. SPEAR T-cell about been to, now

Nicholas Abbott

a you approach? my across you do or what the products, question combination both have these And XX, last tumors. safety What you about will expression since established follow-up you. tumors since various and now safety see X and for of antigens that established, was are is, Thank express both think about

Rafael Amado

definitely of of will consider something be both will established that this again the and possibility thinking both. We about we have -- the combining safety we once think

are In patients. terms positive. you're positives positive AXX a right, are majority AXX expression, of There of than are AX patients the that lot AX also more

priorities best So whether that see I think, both second that need the test, have written against in have you've AXX to next fits patients in generations trial sequentially thinking concomitantly. And test way to targets actively to or year we starts the potentially within new new because test to test. the to coming products receive that a we we what just we're in we that. about products either Whether to are heard, is as or subsequently, could combinations way have and that

we're So preparing -- and for trial. pivotal

sure that is execute with about that could [Indiscernible], it but potentially are future. make and partners So we we'll something the we in thinking other have to

Operator

Bank of Merrill question Huang Our Lynch. from next comes America Ying of

open. is line Your

Jenny Leeds

Thank our you so questions. taking guys. Ying. for Hi, for on It's Jenny much

The SRC first about is the just up a where you clarification. In XK dosing. the talked

who X patients study. of that X then in billion cohort and million cells X in cancer received you both cells mentioned the talked You studies, XXX the of the lung patients about received second

the But I the third SRC in Just the just cohort dosed that study dose was to have didn't wondering second if use of there? know and clarification you basket up wanted that Cohort. order the get data MAGE-AXX data. to the some actually to

Rafael Amado

the I a total X. X dosing Cohort in cells based actively try. safety billion dosing cohort was trials, non-small patients we the cell SRC in in a way question. through cancer. all I'm about lung -- dosed the X both it the the the cancer XXX give But I'll on have We that X at at AXX cancer. and patients And And cell fully lung then sure. recommended a not Well, understood cells dose study. tumor in lung X triple escalation the X million of the between trials. And we're non-small

billion the are cohort, are both third studies. is in which to going into X X.X So billion currently we

we AXX. are where And that's so with

Jenny Leeds

Right.

dosed is question was you trial ever So said X I were with dosed? of X billion. the guess Because basket the the trial Cohort cancer patients - X lung in

Rafael Amado

the cancer study, that is that on billion. X based we SRC that of lung safety recommended to moved So we've the bypass on the so cohort,

Jenny Leeds

Okay. Yes, I that's thought. what

data multiple see there have per would mature, Thank then to about present clarify. scans, the want you in trying rates, meeting? more we could response PR considered many to Just likely a be know think want a mature? just to before the data data patient expecting And of what's or to want we you. scans you that you the would you as how that when to terms present would I full think at medical that And be just

James Noble

difficulties their doctors data and I we'd in submit X patients clearly wait it's is the about for X and studies. responses are the do own a And whether can't in a like We had alluded these obviously unfortunately they've medical response not, to or the therapy earlier conference what that. months do, are and all because know cell So which to even material. advance or fact -- obviously, that open-label actually to

model MRCLS you at should data we So it the for get terms a the about had that this where talked the lot forward. going quarterly the be we is ASCO, to was model looking model and that sort And at -- year, data think, earlier used think I I a materiality presentation, we a because rough of then we at out, follow of an in the presentation the that's of actually up responses. oral with

update confirmed we X of XX means in general And reason apart. scans, so which But I not X basically So like the terms have X. to only -- the patient-by-patient, trying responses, a program. we responses, the across wouldn't to is that days we'd to do like we to think if present would or we're give go going were

second an So commenting that scan have which X unconfirmed the but response X not we on as patients, we're mean we give would well, might X all if apart. weeks

So as out earnings response we we up of do we -- at we'll will so follow in essentially, outlines an soon we of a call thereafter. or it And broad release conference the medical as sort will of then data. either put can -- press a it

Operator

any the for further call over turn like closing back no to are Noble James questions. I'd remarks. to There

James Noble

our can into Great. patients our excellent we really up and got questions a great as everybody all programs. MAGE-AXX listening own Well, and We resources MAGE-AX. of where thanks are lined at both a moment very runway put really We've for for exciting usual.

when forward of up get before So as that we and and data I will year, the of that the I lot this with look end very come we to confident am a presenting responses.

thank very much. So you

Operator

day. may thank Everyone a you disconnect. conference. all in program for gentlemen, today's and This conclude participating does and have Ladies you great the

Adaptimmune Therapeutics (ADAP) 4 Aug 182018 Q2 Earnings call transcript